image credit- shutterstock
TaiGen Biopharmaceuticals Holdings has announced that TaiGen Biotechnology, a subsidiary company of TaiGen, has signed an exclusive licensing agreement with Y.S.P. Industries (M) Sdn. Bhd. to develop and commercialise TaiGen's new drug in Malaysia and Singapore.
TaiGen indicates that the agreement involves the development and marketing rights of the new drug in Malaysia and Singapore. Y.S.P. Industries (M) Sdn. Bhd. will be responsible for the New Drug Application (NDA) and market sales within the authorised region. The contract duration starts from the signing date and lasts for 20 years from the initial product sale.
TaiGen Biotechnology, with a subsidiary in Beijing, China, was founded in 2001 and became listed on the Taiwan OTC Stock Market in 2014. The company possesses the capability to conduct multi-country, multi-center clinical trials and has a track record of overseas licensing. Its flagship product, non-fluorinated quinolone antibiotic Taigexyn® (Nemonoxacin), has obtained marketing approvals in Taiwan, mainland China, and Russia. The influenza antiviral TG-1000 has completed the phase II clinical trial and out-licensed the development and commercialization rights in mainland China.
